Study of ORMD-0801 for Type 2 Diabetes Mellitus
This study is looking at an investigational oral capsule called ORMD-0801 for people with Type 2 Diabetes Mellitus (T2DM) whose blood sugar isn't well-controlled with their current medications. Researchers want to see how safe and effective different doses of ORMD-0801 are. You might be able to join if you are at least 50 years old, have T2DM, and your A1C (a measure of average blood sugar) is between 7.2% and 10.0%. The main goal is to see how much ORMD-0801 changes your A1C after 26 weeks. About 300 people will participate in this study. The current status of the study is unclear.
- Study design
- This is a randomized, double-blind, placebo-controlled study, meaning participants will be randomly assigned to receive either ORMD-0801 or a placebo (an inactive substance), and neither you nor your doctor will know which you are receiving. Approximately 300 participants will be enrolled.
- What's involved
- You would undergo a 4-week screening period, followed by a 26-week treatment period. This includes visits for screening, placing and removing a continuous glucose monitoring (CGM) sensor, and follow-up appointments.
- Compensation
- Not stated in the trial record.
- Follow-up
- There will be a safety follow-up visit four weeks after the completion of the 26-week treatment period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT06731075
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
Not Yet Recruiting
PHASE3Ages 50+InterventionalTreatmentOramed, Ltd.
~300 participants
Updated 2025-08-03 on ClinicalTrials.gov
What's tested:ORMD-0801 8 mgPlacebo capsuleORMD-0801 16 mg
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from baseline in A1C at 26 weeks
Measured over Visit 1 (baseline) and Visit 6 (week 26)
Conditions
Where it's being run
1 sites across 1 statesTexas1
Study leadership
- Miriam Kidron, Ph.D. · STUDY_DIRECTOR · Oramed, Ltd.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Male and female subjects aged ≥ 50 years.
Established diagnosis of T2DM for at least 6 months prior to Screening AND an A1C ≥ 7.2% but ≤ 10.0% at Screening.
On a stable dose of at least one and up to three of the following glucose-lowering agents: Metformin, sulfonylurea, DPP-4 inhibitor, SGLT-2 inhibitor, thiazolidinedione, insulin secretagogue, oral or injected GLP-1 receptor agonists, glucosidase inhibitor, or pramlintide (injected insulin is excluded) for a minimum of 3 months prior to Screening.
Body mass index (BMI) of ≤ 28 kg/m2 at Screening and stable weight, with no more than 5 kg gain or loss in the 3 months prior to Screening.
Renal function - eGFR ≥ 30 ml/min.
Females of childbearing potential must:
\- a. Have a negative serum pregnancy test result at Screening.
\- b. Agree to avoid becoming pregnant while receiving IP for at least 30 days prior to IP administration, during the entire study, and for 30 days following their last dose of IP.
\- c. Agree to use an acceptable method of contraception at least 30 days prior to IP administration, during the entire study, and for 30 days following their last dose of IP. Acceptable methods of contraception are hormonal contraception (contraceptive pill or injection) PLUS an additional barrier method of contraception such as a diaphragm, condom, sponge, or spermicide.
\- d. In the absence of hormonal contraception, double-barrier methods must be used which include a combination of any two of the following: diaphragm, condom, copper intrauterine device, sponge, or spermicide, and must be used for at least 30 days prior to administration of IP, during the entire study, and for 30 days following their last dose of IP.
\- e. Abstinence (relative to heterosexual activity) can be used as the sole method of contraception if it is consistently employed as the subject's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ERCs/IRBs. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.
\- f. Females who are not of childbearing potential are defined as:
\- - - - - i. Postmenopausal (defined as at least 12 months with no menses in women ≥ 45 years of age); OR
\- - - - - ii. Have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; OR
\- - - - - iii. Have a congenital or acquired condition that prevents childbearing.
Exclusion
Type 1 diabetes by history.
Diabetes attributable to other secondary causes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant).
Treatment involving injected insulin within 3 months prior to Visit 1.
A history of \> 2 episodes of severe hypoglycemia within 6 months prior to Screening.
A history of hypoglycemic unawareness.
A history of unstable angina or myocardial infarction within 6 months prior to Screening, New York Heart Association (NYHA) Grade 3 or 4 congestive heart failure (CHF), valvular heart disease, ventricular cardiac arrhythmia requiring treatment, pulmonary hypertension, cardiac surgery, coronary angioplasty, stroke, or transient ischemic attack (TIA) within 6 months prior to Screening.
A history of uncontrolled or untreated severe hypertension defined as systolic blood pressure above or equal to 160 mmHg and/or diastolic blood pressure above or equal to 100 mmHg. A single repeat measurement will be permitted
Renal dysfunction: eGFR \< 30 mL/min.
A history of or active proliferative retinopathy requiring treatment.
Psychiatric disorders that, per Investigator judgment, may have impact on the safety of the subject or interfere with subject's participation or compliance in the study.
Laboratory abnormalities at Screening including:
\- - a. Abnormal serum thyrotropin (TSH) levels below the lower limit of normal or \>1.5X the upper limit of normal; a single repeat test is allowable.
\- - b. Elevated liver enzymes (alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP)) \> 3X the upper limit of normal; a single repeat test is allowable.
\- - c. Very elevated fasting triglyceride levels (\> 600 mg/dL); a single repeat test is allowable.
\- - d. Any relevant abnormality that would interfere with the efficacy or the safety assessments during study treatment administration.
Positive history of active liver disease (other than non-alcoholic hepatic steatosis), primary biliary cirrhosis, or active symptomatic gallbladder disease.
Positive results for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C virus ribonucleic acid (RNA).
Patient has active or history of neoplastic disease (except for adequately treated non-invasive basal cell and/or squamous cell carcinoma or carcinoma in situ of the cervix) within the past 5 years prior to baseline.
Use of the following medications:
\- - -a. History of use of any injectable insulin (greater than 7 days) within 6 months prior to Screening.
\- - -b. Administration of thyroid preparations or thyroxine (except in subjects on stable replacement therapy) within 6 weeks prior to Screening.
\- - - c. Use of oral, intravenous, or intramuscular steroids for one month prior to enrollment. Intra-articular and/or topical corticosteroids are not considered systemic.
\- - - d. Concurrent use of medications known to modify glucose metabolism or to decrease the ability to recover from hypoglycemia such as oral, parenteral, and immunosuppressive or immunomodulating agents. Inhaled nasal steroids are permissible.
Known allergy to soy.
Involvement in a weight loss program and is not in the maintenance phase, or subject has started weight loss medication (e.g., orlistat or liraglutide) within 3 months prior to Screening.
Prior bariatric surgery.
Subject is pregnant or breast-feeding.
Subject is a user of recreational or illicit drugs or has had a recent history (within 1 year of Screening) of drug or alcohol abuse or dependence. (Note: Alcohol abuse includes heavy alcohol intake as defined by \> 3 drinks per day or \> 14 drinks per week or binge drinking) at Screening. Occasional intermittent use of cannabinoid products will be allowed provided that no cannabinoid products have been used during the 1 week prior to each visit.
Weight loss preparations either approved and marketed or used in OTC preparations except for GLP-1 used in the treatment of underlying diabetes.
Any condition or other factor (at the Investigator's discretion) that is deemed unsuitable for subject enrollment into the study.
What this trial measures
- Change from baseline in A1C at 26 weeksVisit 1 (baseline) and Visit 6 (week 26)
Change from baseline (Visit 1) in A1C at 26 weeks (Visit 6).